Our Mission

To discover novel therapeutics that will stop the progression
of neurodegenerative diseases by targeting their underlying causes.

Our Programs

CURRENT CLINICAL TRIALS 

UCB0599 Phase 1b in PD Patients

News

Neuropore Therapies Licenses Autophagy Modulators to Global Cancer Technology for Treatment of Cancers and Other Life-Threatening Diseases
September 30, 2020

Neuropore Therapies, Inc. announced today that it has licensed two mechanistically distinct classes of potent, selective and brain penetrating modulators of mTOR–regulated autophagy to Global Cancer Technology.  

See All News

NPT® Publications

Neuropore publishes paper describing preclinical in vivo characterization of  small molecule targeting α-synuclein as a potential Parkinson's disease therapeutic
November 2nd, 2018

Report in Scientific Reports, describes the beneficial effects of NPT200-11 on multiple disease relevant endpoints in a transgenic mouse model of Parkinson's disease.

See All Publications

 

 

A team poised for success

About Our Team

Our Partners




Corporate

UCB Logo


Foundations & Academic InstitutionsSEE ALL

The Michael J. Fox Foundation for Parkinson's Research
Albert Einstein College of Medicine
University of Sydney

Connect with Neuropore